{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"VEBrant","nct_id":"NCT07153887","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=vebrant-nct07153887. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"subjects will receive Vebreltinib (200 mg bid po) , until disease progression, intolerable toxicity, or death. Subjects will undergo MET abnormality testing after enrollment, including MET amplification or MET protein overexpression.","label":"Vebreltinib Arm","type":"EXPERIMENTAL"},{"description":"Subjects diagnosed with CCS and met the inclusion criteria but refused to enter Cohort1 will receive the standard treatment decided by investigators.","label":"External reference arm","type":"OTHER"}],"collaborators":[],"completion_date":{"date":"2027-07-15","type":"ESTIMATED"},"conditions":["Clear Cell Sarcoma (CCS)"],"enrollment":{"count":30,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Vebreltinib","otherNames":["BoRuiTiNi"],"type":"DRUG"},{"name":"Standard medical treatment","otherNames":[],"type":"OTHER"}],"last_update":"2025-09-30","lead_sponsor":"Second Affiliated Hospital, Zhejiang University, School of Medicine","official_title":"An Exploratory Clinical Trial of Vebreltinib for the Treatment of Patients With Locally Advanced or Metastatic Clear Cell Sarcoma","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-07-15","type":"ESTIMATED"},"primary_outcomes":[{"measure":"ORR","timeFrame":"up to 24 months"}],"references":[{"citation":"Jiang Y, Lin N, Huang X, Yan X, Liu M, Qu H, Li X, Lin P, Li H, Ye Z, Li B. VEBrant: a multicenter, phase II study of MET inhibitor vebreltinib combined with PD-1-based immunotherapy in advanced clear cell sarcoma. Future Oncol. 2026 Jul;22(17):2047-2053. doi: 10.1080/14796694.2026.2695212. Epub 2026 Jun 30.","pmid":"42376809","type":"DERIVED"}],"start_date":{"date":"2025-09-30","type":"ESTIMATED"},"study_type":"INTERVENTIONAL","title":"Vebreltinib for Advanced or Metastatic CCS","url":"https://clinicaltrials.gov/study/NCT07153887"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/vebrant-nct07153887"}